Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.
Nimri R, Bratina N, Kordonouri O, Avbelj Stefanija M, Fath M, Biester T, Muller I, Atlas E, Miller S, Fogel A, Phillip M, Danne T, Battelino T. Nimri R, et al. Among authors: bratina n. Diabetes Obes Metab. 2017 Apr;19(4):553-561. doi: 10.1111/dom.12852. Epub 2017 Jan 19. Diabetes Obes Metab. 2017. PMID: 27981804 Clinical Trial.
AIMS: To evaluate the safety, efficacy and need for remote monitoring of the MD-Logic closed-loop system during short-term overnight use at home. ...RESULTS: The median [interquartile range] percentage of time spent in hypoglycaemia was significantly lower on nights when …
AIMS: To evaluate the safety, efficacy and need for remote monitoring of the MD-Logic closed-loop system during short-term overnight …
Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis.
Nimri R, Muller I, Atlas E, Miller S, Kordonouri O, Bratina N, Tsioli C, Stefanija MA, Danne T, Battelino T, Phillip M. Nimri R, et al. Among authors: bratina n. Pediatr Diabetes. 2014 Mar;15(2):91-9. doi: 10.1111/pedi.12071. Epub 2013 Aug 15. Pediatr Diabetes. 2014. PMID: 23944875 Clinical Trial.
OBJECTIVE: To assess the feasibility, safety, and efficacy of the MD-Logic AP in controlling nocturnal glucose levels in the patient's home. METHODS: Two-arm study, each covering four consecutive nights comparing the MD-Logic AP ('closed-loop' arm) with sensor-augme …
OBJECTIVE: To assess the feasibility, safety, and efficacy of the MD-Logic AP in controlling nocturnal glucose levels in the patient' …
DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
Biester T, Nir J, Remus K, Farfel A, Muller I, Biester S, Atlas E, Dovc K, Bratina N, Kordonouri O, Battelino T, Philip M, Danne T, Nimri R. Biester T, et al. Among authors: bratina n. Diabetes Obes Metab. 2019 Apr;21(4):822-828. doi: 10.1111/dom.13585. Epub 2018 Dec 21. Diabetes Obes Metab. 2019. PMID: 30478937 Clinical Trial.
AIMS: Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD-Logic closed-loop system (DreaMed GlucoSitter) in different settings for overnight glycaemic control. ...All participants were connected in randomized order for one weekend to SAP therapy …
AIMS: Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD-Logic closed-loop system (DreaMed GlucoSitter) …
MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial.
Nimri R, Muller I, Atlas E, Miller S, Fogel A, Bratina N, Kordonouri O, Battelino T, Danne T, Phillip M. Nimri R, et al. Among authors: bratina n. Diabetes Care. 2014 Nov;37(11):3025-32. doi: 10.2337/dc14-0835. Epub 2014 Jul 30. Diabetes Care. 2014. PMID: 25078901 Clinical Trial.
OBJECTIVE: We evaluated the effect of the MD-Logic system on overnight glycemic control at patients' homes. ...CONCLUSIONS: The long-term home use of automated overnight insulin delivery by the MD-Logic system was found to be a feasible, safe, and an effective tool …
OBJECTIVE: We evaluated the effect of the MD-Logic system on overnight glycemic control at patients' homes. ...CONCLUSIONS: The long- …
The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T. Nimri R, et al. Among authors: bratina n. Pediatr Diabetes. 2013 May;14(3):159-67. doi: 10.1111/pedi.12025. Epub 2013 Feb 28. Pediatr Diabetes. 2013. PMID: 23448393 Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of the closed-loop MD-Logic Artificial Pancreas (MDLAP), controlling nocturnal glucose levels in patients with type 1 diabetes mellitus (T1DM). ...
OBJECTIVE: To assess the safety and efficacy of the closed-loop MD-Logic Artificial Pancreas (MDLAP), controlling nocturnal glucose l …
Reduced Worries of Hypoglycaemia, High Satisfaction, and Increased Perceived Ease of Use after Experiencing Four Nights of MD-Logic Artificial Pancreas at Home (DREAM4).
Ziegler C, Liberman A, Nimri R, Muller I, Klemenčič S, Bratina N, Bläsig S, Remus K, Phillip M, Battelino T, Kordonouri O, Danne T, Lange K. Ziegler C, et al. Among authors: bratina n. J Diabetes Res. 2015;2015:590308. doi: 10.1155/2015/590308. Epub 2015 Oct 25. J Diabetes Res. 2015. PMID: 26581230 Free PMC article.
METHODS: In a multicentre, multinational study of 75 patients using the MD-Logic AP during four consecutive nights in home setting 59 of them (aged 10-54 years, 54% male, HbA1c 7.89 0.69% [62.72 7.51 mmol/mol], diabetes duration 11.6 8.4 yrs) answered standardized question …
METHODS: In a multicentre, multinational study of 75 patients using the MD-Logic AP during four consecutive nights in home setting 59 …